RENALYTIX AI, INC.


Associated tags: Kidney disease, Patient, CKD, Chronic kidney disease, Risk assessment, DKD, SALT, LSE, Pharmaceutical industry

Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems

Retrieved on: 
Monday, January 9, 2023
Cloud, United States Department of Veterans Affairs, VistA, Cooperative, GSA, Research and development agreement, SALT, Ecosystem, Information technology, Development, Cerner, Information technology architecture, Government, CRADA, Risk assessment, Version, Department of Defence, Hampton VAMC National Cemetery, Manchester VA Medical Center, Recognition, Veterans Health Administration, Kidney disease, CKD, Chronic kidney disease, Patient, General Services Administration, OIT, St. Cloud VA Health Care System, DKD, CPRS, United States Department of Defense, LSE, VHA, Hospital, Pharmaceutical industry, Veteran

LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with the U.S. Veterans Health Administration Innovation Ecosystem (VHA IE) to install the KidneyIntelX solution inside the VA Health System’s Cloud Infrastructure and interface it with the VA Electronic Health Record Systems.

Key Points: 
  • LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with the U.S. Veterans Health Administration Innovation Ecosystem (VHA IE) to install the KidneyIntelX solution inside the VA Health System’s Cloud Infrastructure and interface it with the VA Electronic Health Record Systems.
  • By installing the KidneyIntelX platform inside the VA infrastructure through this innovative approach, one of the first such implementations by the VA, the stringent requirements for the security of Veteran’s health information and data will be assured.
  • According to the March 17, 2020, Veterans Health Administration (VHA) Directive 1053, approximately 960,000 Veterans, or 11%, meet the established criteria for chronic kidney disease (CKD).
  • However, less than half of those Veterans, 320,000, or 5%, have been formally diagnosed with CKD.

Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes

Retrieved on: 
Thursday, December 1, 2022
Hypertension, Doctor of Philosophy, SALT, Public health, PCP, Conditional sentence, Kidney disease, Attention, Centers for Disease Control and Prevention, T2D, Food, Dialysis, Risk, SGLT2, Physician, DKD, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Kidney, Risk assessment, The American Journal of Managed Care, De novo, Disease, Standard of care, MD, LSE, Diabetes, EGFR, SBP, Medicare, Chronic kidney disease, Journal, CKD, Kidney failure, American Journal, Community health, Pharmaceutical industry, Albuminuria

By integrating a simple, actionable KidneyIntelX risk assessment result, primary care physicians are able to determine the appropriate and cost-effective treatment plan for their individual patients based on their risk level.

Key Points: 
  • By integrating a simple, actionable KidneyIntelX risk assessment result, primary care physicians are able to determine the appropriate and cost-effective treatment plan for their individual patients based on their risk level.
  • The ability to predict CKD risk early could improve care and outcomes by reducing cardiovascular events, hospitalizations and emergency room visits.
  • Medicare alone spends an estimated $85 billion on early stage CKD care each year, more than double the $37 billion spent on end stage kidney disease care.
  • By addressing kidney disease early, providers can better allocate resources and reduce costs across all stages of the disease.

Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease

Retrieved on: 
Tuesday, November 29, 2022

LONDON and SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the publication of new real-world evidence (RWE) in Primary Care and Community Health demonstrating the Company’s KidneyIntelX bioprognostic™ test resulted in changed clinical decision making for patients in the early-stage of diabetic kidney disease (DKD) being cared for within the Mount Sinai Health System’s Population Health Ambulatory Pharmacy and Condition Management programs. The majority of patients were being treated by their primary care physician.

Key Points: 
  • The data is greatly encouraging for millions of early stage 1-3 DKD patients where we lack patient-specific risk assessment tools to adjust appropriate care.
  • Enabling primary care physicians to recognize risk and clinically manage patients with DKD can potentially eliminate unnecessary events from uncontrolled disease progression, including kidney failure and dialysis.
  • Thus, KidneyIntelX enabled physicians to take guideline-recommended clinical actions in high risk, early stage (stage 1-3b) diabetic kidney disease patients.
  • We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs.